Kyntra Bio (NASDAQ:KYNB) Stock Gets Downgrade from Zacks Research

Kyntra Bio (NASDAQ:KYNB) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Monday, Zacks reports.

Several other research analysts also recently commented on KYNB. Weiss Ratings downgraded shares of Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday. Oppenheimer assumed coverage on shares of Kyntra Bio in a report on Monday, July 6th. They issued an “outperform” rating and a $35.00 price target on the stock. Maxim Group started coverage on shares of Kyntra Bio in a report on Tuesday. They issued a “buy” rating and a $35.00 price target on the stock. Lake Street Capital initiated coverage on Kyntra Bio in a research report on Thursday, September 17th. They issued a “buy” rating and a $41.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $43.00 price objective on shares of Kyntra Bio in a research report on Tuesday, September 1st. Five investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Kyntra Bio currently has an average rating of “Hold” and a consensus target price of $36.80.

Kyntra Bio Trading Down 4.1%

Kyntra Bio stock opened at $5.87 on Monday. The firm’s 50 day simple moving average is $7.26 and its 200 day simple moving average is $7.12. The firm has a market capitalization of $23.77 million, a PE ratio of 0.13 and a beta of 1.05. Kyntra Bio has a 1-year low of $5.62 and a 1-year high of $11.65.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC acquired a new position in Kyntra Bio Inc (NASDAQ:KYNB) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio at the end of the most recent quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.